Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies. Pfizer’s GMG competitive grant program involves a publicly posted general Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the research gaps as outlined in the specific RFP.
Projects that will be considered for Pfizer support will focus on: • Morbidity and mortality in patients with Acromegaly/GH Excess • Novel strategies including Quality of Life and Patient Reported Outcomes to evaluate and treat acromegaly/GH Excess • Early diagnosis and treatment of acromegaly/GH Excess; consequences of late diagnosis/treatment initiation • Pharmacoeconomics such as but not limited to resource utilization; patient-reported outcomes; treatment patterns
Grant Application due date: October 1, 2019
Geographic Scope: Global (all countries eligible)
• The institution and principal investigator (PI) must be based in one of the eligible countries noted above. • Only organizations are eligible to receive grants, not individuals or medical practice groups. • The applicant (PI) must have a medical or postdoctoral degree (MD, PhD, or equivalent), an advanced nursing degree (BSN with a MS/PhD), or a degree in Pharmacy, Physiotherapy, or Social Work. • Applicant must be affiliated with a host institution
Individual projects requesting up to $50,000/year for 1 to 2 years will be considered. Pfizer anticipates awarding up to 2 grants
